By Editor • September 5, 2026 • 1 min read
An innovative trial will test an experimental Alzheimer’s drug on healthy individuals at risk, aiming to prevent dementia before symptoms appear.
Read moreBy Editor • September 2, 2026 • 1 min read
Ultragenyx's GTX-102 for Angelman syndrome has failed a Phase 3 trial, dashing hopes for affected families and the company's profitability.
Read moreBy Editor • August 30, 2026 • 1 min read
An arthritis drug has shown remarkable results, restoring complete hair growth in patients with severe alopecia areata during a global trial.
Read moreBy Editor • August 28, 2026 • 1 min read
AstraZeneca's heart disease drug trial failed to show benefits for patients already on stabilizers, impacting the broader ATTR-CM market.
Read moreBy Editor • August 20, 2026 • 1 min read
A Chinese hospital reports that a new stem cell therapy has led to significant heart function recovery in 90% of severe heart failure patients.
Read moreBy Editor • August 20, 2026 • 1 min read
Merck and Moderna's mRNA cancer therapy success marks 2026 as a pivotal year in cancer treatment advancements.
Read moreBy Editor • August 20, 2026 • 1 min read
Capricor Therapeutics' efforts to prevent FDA rejection of its Duchenne muscular dystrophy treatment appear futile, requiring a new clinical trial for approval.
Read moreBy Editor • August 19, 2026 • 1 min read
Merck and Moderna's personalized mRNA therapy intismeran autogene achieves a milestone in melanoma treatment with positive phase 3 trial results.
Read moreBy Editor • August 19, 2026 • 1 min read
Moderna and Merck's mRNA cancer vaccine shows promise in a Phase 3 trial for melanoma, highlighting advancements in personalized cancer treatment.
Read moreBy Editor • August 19, 2026 • 1 min read
A new mRNA drug has shown promising results in preventing melanoma recurrence, marking a milestone in cancer treatment.
Read more
